Action SYNGENE SYNGENE INTERNATIONAL LIMITED
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Syngene International Limited Bombay S.E.

Actions

SYNGENE

INE398R01022

Marché Fermé - Bombay S.E.
Autres places de cotation
 12:00:50 03/05/2024 		Varia. 5j. Varia. 1 janv.
678,7 INR -1,27% Graphique intraday de Syngene International Limited -2,80% -3,20%
26/04 SYNGENE INTERNATIONAL LIMITED : Jefferies & Co. n'est plus neutre mais vendeur ZM
25/04 Transcript : Syngene International Limited, Q4 2024 Earnings Call, Apr 25, 2024

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Syngene International Limited Submits an Appeal to the National Faceless Appeal Centre, for Assessment Year 2022-23
Syngene International Limited Submits an Appeal to the Commissioner of Income-Tax-12, Bangalore, for Assessment Year 2017-18 and 2018-19
Syngene International Limited Recommends Final Dividend for the Financial Year 2024
Syngene International Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024
Syngene International Limited Reports Earnings Results for the Full Year Ended March 31, 2024
Syngene International Limited Submits an Appeal to the Commissioner of Income-Tax-12, Bangalore, for Assessment Year 2013-14 and 2014-15
INDIA STOCKS-Financials drag Indian shares, hit by fading US rate cut hopes
Syngene Biologics Manufacturing Facility to Be Operational for U.S. and European Customers from Mid-Year
Bristol Myers CEO says India to have largest R&D presence outside US by 2025
Syngene International Posts Gains in Fiscal Q3 Consolidated Net Profit
Syngene International Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
Syngene International Limited Appoints Mr. Sibaji Biswas as Additional Director Designated as Executive Director, Effective on April 01, 2024
Syngene International Completes Acquisition of Stelis Biopharma's Biologics Plant
Syngene International Limited completed the acquisition of Unit 3 biologics manufacturing facility in Bangalore from Stelis Biopharma Private Limited for INR 6.2 billion.
FOCUS -Indian drug manufacturers benefit from Big Pharma interest beyond China
Syngene International COO Steps Down
Syngene International Limited Announces Resignation of Mahesh Bhalgat as Chief Operating Officer, Effective January 31, 2024
Syngene International Limited Announces Resignation of Carl Decicco as Non-Executive Director
Syngene International's Consolidated Profit Jumps in Fiscal Q2; Shares Slump 7%
Syngene International Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action SYNGENE
  4. Action SYNGENE
  5. Actualités Syngene International Limited
  6. Autres langues